Timo Müller

Director / Prof. Dr.

Helmholtz Zentrum München

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Prof. Dr. Timo Müller is the Director at Helmholtz Zentrum München in Germany. His research focuses on obesity pharmacotherapy, specifically the roles of incretins and novel medication strategies for weight management. His recent publications explore the physiological effects of incretin receptor agonists and advancements in indirect calorimetry data analysis.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (4)

Lillian Garrett

Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit

GERMANY

View details

Georg Sebastian Hönes

University Hospital Essen

GERMANY

View details

Juan Antonio Aguilar-Pimentel

Senior Scientist / Head Lab

Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit

GERMANY

View details

Cristina García-Cáceres

W2 Professor

LMU Klinikum

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Timo Müller

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Tirzepatide differentially affects body weight in mice and humans

Calopy — an advanced framework for the integration and analysis of indirect calorimetry data

Glucose-dependent insulinotropic polypeptide (GIP)

Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes

Comparative Phenotyping of Mice Reveals Canonical and Noncanonical Physiological Functions of TRα and TRβ

The role of incretin receptor agonists in the treatment of obesity

Antagonizing GIPR adds fire to the GLP-1R flame

Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

Recent achievements and future directions of anti-obesity medications

Why are we still in need for novel anti-obesity medications?

(Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins II: Intercellular Transfer of Matter (Inheritance?) That Matters

(Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins I: Localization at Plasma Membranes and Extracellular Compartments

Transfer of Proteins from Cultured Human Adipose to Blood Cells and Induction of Anabolic Phenotype Are Controlled by Serum, Insulin and Sulfonylurea Drugs

Rest phase snacking increases energy resorption and weight gain in male mice

Validation of Mct8/Oatp1c1 dKO mice as a model organism for the Allan-Herndon-Dudley Syndrome.

Collaborators (4)

Lillian Garrett

Georg Sebastian Hönes

Juan Antonio Aguilar-Pimentel

Cristina García-Cáceres

Make your next move.